MCID: CHL156
MIFTS: 38

Childhood T-Cell Acute Lymphoblastic Leukemia

Categories: Blood diseases, Cancer diseases, Immune diseases

Aliases & Classifications for Childhood T-Cell Acute Lymphoblastic Leukemia

MalaCards integrated aliases for Childhood T-Cell Acute Lymphoblastic Leukemia:

Name: Childhood T-Cell Acute Lymphoblastic Leukemia 12 15
Childhood Precursor T-Lymphoblastic Lymphoma/leukemia 12
T-Cell Childhood Acute Lymphoblastic Leukemia 54
T-Cell Childhood Acute Lymphocytic Leukemia 12

Classifications:



External Ids:

Disease Ontology 12 DOID:0080145
NCIt 49 C5640
UMLS 71 C1332997

Summaries for Childhood T-Cell Acute Lymphoblastic Leukemia

Disease Ontology : 12 A childhood acute lymphoblastic leukemia that has material basis in T-cells.

MalaCards based summary : Childhood T-Cell Acute Lymphoblastic Leukemia, also known as childhood precursor t-lymphoblastic lymphoma/leukemia, is related to precursor t-cell acute lymphoblastic leukemia and acute leukemia. An important gene associated with Childhood T-Cell Acute Lymphoblastic Leukemia is TAL1 (TAL BHLH Transcription Factor 1, Erythroid Differentiation Factor), and among its related pathways/superpathways are PI3K-Akt signaling pathway and Common Cytokine Receptor Gamma-Chain Family Signaling Pathways. The drugs Thioguanine and Daunorubicin have been mentioned in the context of this disorder. Affiliated tissues include t cells, bone marrow and bone, and related phenotypes are hematopoietic system and endocrine/exocrine gland

Related Diseases for Childhood T-Cell Acute Lymphoblastic Leukemia

Diseases in the Childhood T-Cell Acute Lymphoblastic Leukemia family:

Childhood B-Cell Acute Lymphoblastic Leukemia

Diseases related to Childhood T-Cell Acute Lymphoblastic Leukemia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 63)
# Related Disease Score Top Affiliating Genes
1 precursor t-cell acute lymphoblastic leukemia 30.2 TAL1 IL7 CDKN2B CD33 ABL1
2 acute leukemia 29.6 TAL1 IL7 CDKN2B CD33
3 myeloid leukemia 29.0 CDKN1A CD33 CBL ABL1
4 t-cell acute lymphoblastic leukemia 28.5 TAL1 IL7R IL7 CDKN2B CDKN1A CD33
5 lymphoma 28.4 TAL1 CDKN2B CCND2 CBL BRCA2 ANXA5
6 leukemia, acute lymphoblastic 28.3 TAL1 MIR221 IL7R IL7 CDKN2B CD33
7 leukemia, acute myeloid 25.9 TAL1 MIR221 IL7R IL7 CDKN2B CDKN1A
8 leukemia 10.6
9 lymphoblastic lymphoma 10.3
10 severe combined immunodeficiency 10.3
11 lymphoblastic leukemia, acute, with lymphomatous features 10.3 IL7R ABL1
12 childhood acute lymphocytic leukemia 10.3
13 acute kidney failure 10.3
14 mental retardation, autosomal dominant 33 10.2 IL7R ABL1
15 spondylometaphyseal dysplasia, sedaghatian type 10.1
16 fanconi anemia, complementation group d1 10.1
17 meningioma, radiation-induced 10.1
18 meningioma, familial 10.1
19 hermansky-pudlak syndrome 5 10.1
20 leukemia, acute lymphoblastic 3 10.1
21 interleukin-7 receptor alpha deficiency 10.1
22 spinal meningioma 10.1
23 hyperuricemia 10.1
24 hyperostosis 10.1
25 hermansky-pudlak syndrome 10.1
26 secretory meningioma 10.1
27 lymphoplasmacyte-rich meningioma 10.1
28 b-cell lymphoma 10.1
29 t-cell lymphoblastic leukemia/lymphoma 10.1
30 splenomegaly 10.1
31 tetraploidy 10.1
32 triploidy 10.1
33 myelophthisic anemia 10.1 CD33 ABL1
34 lymphopenia 10.0 IL7R IL7 ANXA5
35 b-lymphoblastic leukemia/lymphoma with hyperdiploidy 9.9 CBL BRCA2 ABL1
36 combined t cell and b cell immunodeficiency 9.9 IL7R IL7 ANXA5
37 cardiomyopathy, dilated, 1c, with or without left ventricular noncompaction 9.9 IL7R CD33
38 bone marrow cancer 9.8 CD33 ANXA5 ABL1
39 mixed phenotype acute leukemia 9.6 CD33 ABL1
40 ataxia-telangiectasia 9.6 CDKN1A BRCA2 ABL1
41 adult acute lymphocytic leukemia 9.5 CDKN2B CD33 ABL1
42 coronary restenosis 9.5 CDKN2B CDKN1A
43 gastrointestinal stromal tumor 9.4 CDKN1A CBL ANXA5 ABL1
44 retinal cancer 9.4 CDKN2B CDKN1A CCND2
45 suppression of tumorigenicity 12 9.3 CDKN1A BRCA2 ANXA5
46 glioma 9.3 MIR221 CDKN1A CCND2 BRCA2
47 li-fraumeni syndrome 9.3 CDKN2B CDKN1A BRCA2
48 lymphoma, non-hodgkin, familial 9.3 TAL1 IL7 CDKN2B CCND2 ANXA5
49 melanoma, cutaneous malignant 1 9.2 CDKN2B CDKN1A BRCA2
50 mantle cell lymphoma 9.1 CDKN2B CDKN1A CCND2 ANXA5

Graphical network of the top 20 diseases related to Childhood T-Cell Acute Lymphoblastic Leukemia:



Diseases related to Childhood T-Cell Acute Lymphoblastic Leukemia

Symptoms & Phenotypes for Childhood T-Cell Acute Lymphoblastic Leukemia

MGI Mouse Phenotypes related to Childhood T-Cell Acute Lymphoblastic Leukemia:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 9.9 ABL1 ANXA5 BRCA2 CBL CCND2 CDKN1A
2 endocrine/exocrine gland MP:0005379 9.86 ABL1 BRCA2 CBL CCND2 CDKN1A CDKN2B
3 immune system MP:0005387 9.7 ABL1 ANXA5 BRCA2 CBL CCND2 CDKN1A
4 skeleton MP:0005390 9.23 ABL1 AFF3 ANXA5 BRCA2 CBL CCND2

Drugs & Therapeutics for Childhood T-Cell Acute Lymphoblastic Leukemia

Drugs for Childhood T-Cell Acute Lymphoblastic Leukemia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 94)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Thioguanine Approved Phase 3 154-42-7 2723601
2
Daunorubicin Approved Phase 3 20830-81-3 30323
3
Mitoxantrone Approved, Investigational Phase 3 65271-80-9 4212
4
Vincristine Approved, Investigational Phase 3 57-22-7, 2068-78-2 5978
5
Pegaspargase Approved, Investigational Phase 3 130167-69-0
6
Doxorubicin Approved, Investigational Phase 3 23214-92-8 31703
7
leucovorin Approved Phase 3 58-05-9 6006 143
8
Methylprednisolone Approved, Vet_approved Phase 3 83-43-2 6741
9
Methotrexate Approved Phase 3 59-05-2, 1959-05-2 126941
10
Mercaptopurine Approved Phase 3 50-44-2 667490
11
Prednisolone phosphate Approved, Vet_approved Phase 3 302-25-0
12
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 3 1177-87-3
13
Methylprednisolone hemisuccinate Approved Phase 3 2921-57-5
14
Dexamethasone Approved, Investigational, Vet_approved Phase 3 50-02-2 5743
15
Cyclophosphamide Approved, Investigational Phase 3 50-18-0, 6055-19-2 2907
16 Prednisolone acetate Approved, Vet_approved Phase 3 52-21-1
17
Prednisolone Approved, Vet_approved Phase 3 50-24-8 5755
18
Cytarabine Approved, Experimental, Investigational Phase 3 147-94-4, 65-46-3 6253
19
Etoposide Approved Phase 3 33419-42-0 36462
20
Hydrocortisone Approved, Vet_approved Phase 3 50-23-7 5754
21
Hydrocortisone acetate Approved, Vet_approved Phase 3 50-03-3
22
Levoleucovorin Approved, Investigational Phase 3 68538-85-2
23
Vindesine Approved, Investigational Phase 3 59917-39-4, 53643-48-4 40839
24
Ifosfamide Approved Phase 3 3778-73-2 3690
25
Idarubicin Approved Phase 3 58957-92-9 42890
26
Folic acid Approved, Nutraceutical, Vet_approved Phase 3 59-30-3 6037
27
Prednisolone hemisuccinate Experimental Phase 3 2920-86-7
28 Analgesics Phase 3
29 Gastrointestinal Agents Phase 3
30 Antibiotics, Antitubercular Phase 3
31 Methylprednisolone Acetate Phase 3
32 Hormones Phase 3
33 Antineoplastic Agents, Hormonal Phase 3
34 Vitamin B Complex Phase 3
35 Immunosuppressive Agents Phase 3
36 Antiemetics Phase 3
37 Alkylating Agents Phase 3
38 Folate Phase 3
39 Hormone Antagonists Phase 3
40 Anti-Infective Agents Phase 3
41 Anti-Bacterial Agents Phase 3
42 Folic Acid Antagonists Phase 3
43
Liposomal doxorubicin Phase 3 31703
44
asparaginase Phase 3
45 Dermatologic Agents Phase 3
46 Antiviral Agents Phase 3
47 Tubulin Modulators Phase 3
48 Immunologic Factors Phase 3
49 glucocorticoids Phase 3
50 Antirheumatic Agents Phase 3

Interventional clinical trials:

(show all 22)
# Name Status NCT ID Phase Drugs
1 A Randomized Trial of the I-BFM-SG for the Management of Childhood Non-B Acute Lymphoblastic Leukemia Unknown status NCT00764907 Phase 3 asparaginase;cyclophosphamide;cytarabine;daunorubicin hydrochloride;dexamethasone;doxorubicin hydrochloride;etoposide;ifosfamide;leucovorin calcium;mercaptopurine;methotrexate;prednisone;thioguanine;vincristine sulfate;vindesine
2 The Value of Dexamethasone Versus Prednisolone During Induction and Maintenance Therapy of Prolonged Versus Conventional Duration of L-Asparaginase Therapy During Consolidation and Late Intensification, and of Corticosteroid + VCR Pulses During Maintenance in Acute Lymphoblastic Leukemia and Lymphoblastic Non-Hodgkin Lymphoma of Childhood Unknown status NCT00003728 Phase 3 asparaginase;cyclophosphamide;cytarabine;daunorubicin hydrochloride;dexamethasone;doxorubicin hydrochloride;etoposide;leucovorin calcium;mercaptopurine;methotrexate;methylprednisolone;mitoxantrone hydrochloride;prednisolone;therapeutic hydrocortisone;thioguanine;vincristine sulfate;vindesine
3 Intensive Treatment For T-CELL Acute Lymphoblastic Leukemia and Advanced Stage Lymphoblastic Non-Hodgkin's Lymphoma: A Pediatric Oncology Group Phase III Study Completed NCT01230983 Phase 3 asparaginase;cytarabine;dexrazoxane hydrochloride;doxorubicin hydrochloride;leucovorin calcium;mercaptopurine;methotrexate;prednisone;therapeutic hydrocortisone;vincristine sulfate
4 ALL-BFM 2000 Multi-Center Study for the Treatment of Children and Adolescents With Acute Lymphoblastic Leukemia Completed NCT00430118 Phase 3 asparaginase;cyclophosphamide;cytarabine;daunorubicin hydrochloride;dexamethasone;doxorubicin hydrochloride;etoposide;ifosfamide;mercaptopurine;methotrexate;prednisone;thioguanine;vincristine sulfate;vindesine
5 ALLR3: An International Collaborative Trial for Relapsed and Refractory Acute Lymphoblastic Leukaemia (ALL) Completed NCT00967057 Phase 3 asparaginase;dexamethasone;idarubicin;methotrexate;mitoxantrone hydrochloride;pegaspargase;vincristine sulfate
6 A Multicenter Study of Treatment Protocol for Childhood Acute Lymphoblastic Leukemia in China, 2008. Completed NCT00707083 Phase 3 dexamethasone;mercaptopurine;methotrexate;vincristine sulfate
7 Treatment of Acute Lymphoblastic Leukemia in Children Completed NCT00400946 Phase 3 asparaginase;cyclophosphamide;cytarabine;dexamethasone;dexrazoxane hydrochloride;doxorubicin hydrochloride;etoposide;leucovorin calcium;mercaptopurine;methotrexate;methylprednisolone;pegaspargase;prednisolone;therapeutic hydrocortisone;vincristine sulfate
8 A Phase II Study of 506U78 in Patients With Refractory or Relapsed T-Lineage Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphomas (LBL) Completed NCT00003545 Phase 2 nelarabine
9 TREATMENT OF ISOLATED CNS RELAPSE OF ACUTE LYMPHOBLASTIC LEUKEMIA -- A PEDIATRIC ONCOLOGY GROUP-WIDE PHASE II STUDY Completed NCT00002704 Phase 2 asparaginase;cyclophosphamide;daunorubicin hydrochloride;dexamethasone;etoposide;leucovorin calcium;liposomal cytarabine;mercaptopurine;mesna;methotrexate;therapeutic hydrocortisone;thiotepa;vincristine sulfate
10 Phase I Study of Adoptive Immunotherapy With CD8 Minor Histocompatibility (H) Antigen-Specific CTL Clones for Patients With Relapsed of AML or ALL After Allogeneic Hematopoietic Stem Cell Transplant Completed NCT00107354 Phase 1 cytarabine;etoposide;mitoxantrone hydrochloride
11 A Phase I Study of Photochemically Treated Donor T-Cell Supplements in HLA Haplotype Mismatched Hematopoietic Stem Cell Transplantation Completed NCT00005092 Phase 1 Cyclophosphamide;Psoralen;Thiotepa
12 Assessment of the Long Term Outcome of Childhood ALL Patients Enrolled in EORTC Children's Leukemia Group Trials Between 1971 and 1998 Unknown status NCT01298388
13 Multicentric Study for the Treatment of Children With Acute Lymphoblastic Leukemia Unknown status NCT00343369 asparaginase;cyclophosphamide;cytarabine;daunorubicin hydrochloride;dexamethasone;doxorubicin hydrochloride;mercaptopurine;methotrexate;pegaspargase;prednisolone;teniposide;thioguanine;vincristine sulfate
14 Molecular Taxonomy in Pediatric Cancer- IncRNA Expression in Primary T-ALL Completed NCT01626183
15 Biological Correlates With T-cell Acute Lymphoblastic Leukemia (T-ALL) Gene Expression and Clinical Outcome Completed NCT01295476
16 Molecular Mechanisms of NOTCH Induced Transformation in T-ALL Completed NCT00899366
17 The Metabolic Syndrome in Pediatric Acute Lymphoblastic Leukemia (ALL). Completed NCT00801346
18 Metabolic Pathways in T-Cell Acute Lymphoblastic Leukemia (T-ALL) Completed NCT01581528
19 Treatment of Late Isolated Extramedullary Relapse From Acute Lymphoblastic Leukemia (ALL) (Initial CR1≥ 18 Months) Completed NCT00096135 cyclophosphamide;cytarabine;daunorubicin hydrochloride;dexamethasone;etoposide;leucovorin calcium;mercaptopurine;methotrexate;pegaspargase;therapeutic hydrocortisone;vincristine sulfate
20 The Use of Modified BFM +/- Compound 506U78 (Nelarabine) (NSC# 686673, IND #52611) in an Intensive Chemotherapy Regimen for the Treatment of T-Cell Leukemia Completed NCT00016302 prednisone;vincristine sulfate;daunorubicin hydrochloride;asparaginase;methotrexate;cyclophosphamide;cytarabine;mercaptopurine;leucovorin calcium;dexamethasone;doxorubicin hydrochloride;thioguanine;nelarabine;pegaspargase
21 International Collaborative Treatment Protocol for Infants Under One Year With Acute Lymphoblastic or Biphenotypic Leukemia Recruiting NCT00550992 asparaginase;busulfan;cyclophosphamide;cyclosporine;cytarabine;daunorubicin hydrochloride;etoposide;leucovorin calcium;melphalan;mercaptopurine;methotrexate;mitoxantrone hydrochloride;pegaspargase;prednisolone;prednisone;therapeutic hydrocortisone;thioguanine;vincristine sulfate
22 Translational Research - Observational Study for Identification of New Possible Prognostic Factors and Future Therapeutic Targets in Children With Acute Lymphoblastic Leukemia (ALL) Active, not recruiting NCT01185886

Search NIH Clinical Center for Childhood T-Cell Acute Lymphoblastic Leukemia

Genetic Tests for Childhood T-Cell Acute Lymphoblastic Leukemia

Anatomical Context for Childhood T-Cell Acute Lymphoblastic Leukemia

MalaCards organs/tissues related to Childhood T-Cell Acute Lymphoblastic Leukemia:

40
T Cells, Bone Marrow, Bone, B Cells

Publications for Childhood T-Cell Acute Lymphoblastic Leukemia

Articles related to Childhood T-Cell Acute Lymphoblastic Leukemia:

(show top 50) (show all 89)
# Title Authors PMID Year
1
In vitro susceptibility to dexamethasone- and doxorubicin-induced apoptotic cell death in context of maturation stage, responsiveness to interleukin 7, and early cytoreduction in vivo in childhood T-cell acute lymphoblastic leukemia. 54 61
12010814 2002
2
Inhibition of in vitro spontaneous apoptosis by IL-7 correlates with bcl-2 up-regulation, cortical/mature immunophenotype, and better early cytoreduction of childhood T-cell acute lymphoblastic leukemia. 61 54
10891465 2000
3
Detection of minimal residual disease by PCR in childhood T-cell acute lymphoblastic leukemia with TAL1 gene rearrangement: a preliminary report. 54 61
9950206 1999
4
[TAL1 gene analysis in T-cell malignancies]. 61 54
9597892 1998
5
Clinical significance of TAL1 gene alteration in childhood T-cell acute lymphoblastic leukemia and lymphoma. 54 61
8321044 1993
6
Clinical features and outcome of T-cell acute lymphoblastic leukemia in childhood with respect to alterations at the TAL1 locus: a Pediatric Oncology Group study. 61 54
8471769 1993
7
PTEN and AKT1 Variations in Childhood T-Cell Acute Lymphoblastic Leukemia 61
31744268 2020
8
High CD38 expression in childhood T-cell acute lymphoblastic leukemia is not associated with prognosis. 61
31903984 2020
9
Post-induction Measurable Residual Disease Using Multicolor Flow Cytometry Is Strongly Predictive of Inferior Clinical Outcome in the Real-Life Management of Childhood T-Cell Acute Lymphoblastic Leukemia: A Study of 256 Patients. 61
32391267 2020
10
Childhood T-cell acute lymphoblastic leukemia in a single Latin American center: impact of improved treatment scheme and support therapy on survival. 61
31810895 2019
11
Clinical significance of cytogenetic changes in childhood T-cell acute lymphoblastic leukemia: results of the multicenter group Moscow-Berlin (MB). 61
30067411 2019
12
Fanconi-BRCA pathway mutations in childhood T-cell acute lymphoblastic leukemia. 61
31721781 2019
13
Investigating chemoresistance to improve sensitivity of childhood T-cell acute lymphoblastic leukemia to parthenolide. 61
29773592 2018
14
TCRαβ/CD3 disruption enables CD3-specific antileukemic T cell immunotherapy. 61
29997304 2018
15
Cytokines and soluble HLA-G levels in bone marrow stroma and their association with the survival rate of patients exhibiting childhood T-cell acute lymphoblastic leukemia. 61
28802664 2018
16
Oncogenetic mutations combined with MRD improve outcome prediction in pediatric T-cell acute lymphoblastic leukemia. 61
29051182 2018
17
High-dose methotrexate vs. Capizzi methotrexate for the treatment of childhood T-cell acute lymphoblastic leukemia. 61
30416957 2018
18
TFDP3 confers chemoresistance in minimal residual disease within childhood T-cell acute lymphoblastic leukemia. 61
27902457 2017
19
[Outcome of childhood T-cell acute lymphoblastic leukemia: a report of 99 cases]. 61
27256235 2016
20
Investigating CD99 Expression in Leukemia Propagating Cells in Childhood T Cell Acute Lymphoblastic Leukemia. 61
27764235 2016
21
Prediction of outcomes by early treatment responses in childhood T-cell acute lymphoblastic leukemia: a retrospective study in China. 61
26174476 2015
22
Deregulated WNT signaling in childhood T-cell acute lymphoblastic leukemia. 61
24632884 2014
23
Focal cranial hyperostosis from meningioma: a complication from previous radiation treatment for childhood T-cell acute lymphoblastic leukemia. 61
23459379 2014
24
Extreme hyperleukocytosis in a pediatric T-ALL patient with a rare translocation, t(7;19)(q35;p13), and submicroscopic deletions at 4q25, 7q33 and 10q23. 61
24596673 2014
25
Spontaneous Tumor Lysis Syndrome in Childhood T cell Acute Lymphoblastic Leukemia. 61
31011405 2013
26
Somatic mutation of IL7R exon 6 in acute leukemias and solid cancers. 61
23069254 2013
27
FBXW7 regulates glucocorticoid response in T-cell acute lymphoblastic leukaemia by targeting the glucocorticoid receptor for degradation. 61
23228967 2013
28
A case of childhood T cell acute lymphoblastic leukemia with a complex t(9;9) and homozygous deletion of CDKN2A gene associated with a Philadelphia-positive minor subclone. 61
23044159 2013
29
Promoter DNA methylation pattern identifies prognostic subgroups in childhood T-cell acute lymphoblastic leukemia. 61
23762353 2013
30
Improving outcomes in childhood T-cell acute lymphoblastic leukemia: promising results from the Children's Oncology Group incorporating nelarabine into front-line therapy. 61
26835275 2012
31
Casitas B-cell lymphoma mutation in childhood T-cell acute lymphoblastic leukemia. 61
22591685 2012
32
Absence of biallelic TCRγ deletion predicts induction failure and poorer outcomes in childhood T-cell acute lymphoblastic leukemia. 61
22180181 2012
33
Aberrations of chromosomes 9 and 22 in acute lymphoblastic leukemia cases detected by ES-fluorescence in situ hybridization. 61
22360868 2012
34
DNA methylation pattern is altered in childhood T-cell acute lymphoblastic leukemia patients as compared with normal thymic subsets: insights into CpG island methylator phenotype in T-ALL. 61
21836607 2012
35
The variant translocation of ABL1 gene t(2;9)(q21;q34) in a childhood T-cell acute lymphoblastic leukemia. 61
22380496 2012
36
[Analysis of clinical features and prognostic significance of childhood T-lineage acute lymphoblastic leukemia]. 61
22169311 2011
37
Oncogenic IL7R gain-of-function mutations in childhood T-cell acute lymphoblastic leukemia. 61
21892159 2011
38
Late recurrence of childhood T-cell acute lymphoblastic leukemia frequently represents a second leukemia rather than a relapse: first evidence for genetic predisposition. 61
21357790 2011
39
A DNA-binding mutant of TAL1 cooperates with LMO2 to cause T cell leukemia in mice. 61
21057528 2011
40
Effective treatment of advanced-stage childhood lymphoblastic lymphoma without prophylactic cranial irradiation: results of St Jude NHL13 study. 61
19194463 2009
41
[ALL-XH-99 protocol in the treatment of childhood T-cell acute lymphoblastic leukemia]. 61
19563031 2009
42
Impact of genotype on survival of children with T-cell acute lymphoblastic leukemia treated according to the French protocol FRALLE-93: the effect of TLX3/HOX11L2 gene expression on outcome. 61
18835836 2008
43
Bone marrow ectopic expression of a non-coding RNA in childhood T-cell acute lymphoblastic leukemia with a novel t(2;11)(q11.2;p15.1) translocation. 61
18947387 2008
44
[Characteristics of T cell receptor beta gene rearrangements and its role in minimal residual disease detection in childhood T-cell acute lymphoblastic leukemia]. 61
19099802 2008
45
Identification of the novel AML1 fusion partner gene, LAF4, a fusion partner of MLL, in childhood T-cell acute lymphoblastic leukemia with t(2;21)(q11;q22) by bubble PCR method for cDNA. 61
17968322 2008
46
Targeting transcription factors in acute leukemia in children. 61
17584028 2007
47
A recurrent stop-codon mutation in succinate dehydrogenase subunit B gene in normal peripheral blood and childhood T-cell acute leukemia. 61
17487275 2007
48
The clinical value of follow-up examinations in childhood T-cell acute lymphoblastic leukemia and T-cell non-Hodgkin's lymphoma. 61
16514610 2007
49
Characterization of a progenitor cell population in childhood T-cell acute lymphoblastic leukemia. 61
17003368 2007
50
Superiority of allogeneic hematopoietic stem-cell transplantation compared with chemotherapy alone in high-risk childhood T-cell acute lymphoblastic leukemia: results from ALL-BFM 90 and 95. 61
17179108 2006

Variations for Childhood T-Cell Acute Lymphoblastic Leukemia

Expression for Childhood T-Cell Acute Lymphoblastic Leukemia

Search GEO for disease gene expression data for Childhood T-Cell Acute Lymphoblastic Leukemia.

Pathways for Childhood T-Cell Acute Lymphoblastic Leukemia

Pathways related to Childhood T-Cell Acute Lymphoblastic Leukemia according to GeneCards Suite gene sharing:

(show all 20)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.77 IL7R IL7 HLA-G CDKN1A CCND2
2
Show member pathways
12.56 IL7R IL7 CDKN1A CBL
3
Show member pathways
12.36 CDKN2B CDKN1A CCND2 CBL BRCA2
4 12.32 MIR221 CDKN1A CCND2 ABL1
5
Show member pathways
12.17 MIR221 CDKN1A CCND2 ABL1
6 12.14 CDKN2B CDKN1A CCND2 ABL1
7 12.1 HLA-G CDKN2B CDKN1A CCND2
8
Show member pathways
12.05 IL7R IL7 CDKN1A CCND2 ABL1
9 12.04 HLA-G CDKN2B CDKN1A CCND2
10
Show member pathways
12.01 CDKN2B CDKN1A CCND2
11 11.95 IL7R IL7 CDKN2B CDKN1A CCND2 CBL
12 11.82 HLA-G CDKN2B CDKN1A CCND2
13 11.8 IL7R IL7 CD33
14 11.78 CDKN1A CCND2 ABL1
15 11.68 IL7R IL7 CD33
16
Show member pathways
11.59 IL7R CDKN2B CDKN1A CCND2
17 11.28 MIR221 CDKN1A ABL1
18 11.02 IL7R IL7
20
Show member pathways
10.91 CDKN1A ABL1

GO Terms for Childhood T-Cell Acute Lymphoblastic Leukemia

Cellular components related to Childhood T-Cell Acute Lymphoblastic Leukemia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 external side of plasma membrane GO:0009897 8.92 IL7R HLA-G CD33 ANXA5

Biological processes related to Childhood T-Cell Acute Lymphoblastic Leukemia according to GeneCards Suite gene sharing:

(show all 17)
# Name GO ID Score Top Affiliating Genes
1 negative regulation of cell proliferation GO:0008285 9.85 MIR221 CDKN2B CDKN1A CD33
2 cellular response to DNA damage stimulus GO:0006974 9.77 TFDP3 CDKN1A CBL BRCA2 ABL1
3 regulation of cell cycle GO:0051726 9.71 TFDP3 CDKN1A ABL1
4 cell cycle arrest GO:0007050 9.67 CDKN2B CDKN1A ABL1
5 intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator GO:0042771 9.57 CDKN1A BRCA2
6 response to gamma radiation GO:0010332 9.56 CBL BRCA2
7 cellular senescence GO:0090398 9.52 CDKN2B CDKN1A
8 response to X-ray GO:0010165 9.51 CDKN1A BRCA2
9 negative regulation of G1/S transition of mitotic cell cycle GO:2000134 9.5 TFDP3 CDKN2B CDKN1A
10 cellular response to extracellular stimulus GO:0031668 9.48 CDKN2B CDKN1A
11 negative regulation of phosphorylation GO:0042326 9.46 CDKN2B CDKN1A
12 DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator GO:0006978 9.43 CDKN1A BRCA2
13 megakaryocyte differentiation GO:0030219 9.4 TAL1 CDKN2B
14 regulation of cyclin-dependent protein serine/threonine kinase activity GO:0000079 9.33 CDKN2B CDKN1A CCND2
15 negative regulation of T cell mediated cytotoxicity GO:0001915 9.26 IL7R HLA-G
16 positive regulation of mitotic cell cycle GO:0045931 9.13 TAL1 BRCA2 ABL1
17 negative regulation of apoptotic process GO:0043066 9.1 MIR221 IL7 CDKN1A CCND2 CBL ANXA5

Molecular functions related to Childhood T-Cell Acute Lymphoblastic Leukemia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 ephrin receptor binding GO:0046875 8.96 CBL ABL1
2 cyclin-dependent protein serine/threonine kinase inhibitor activity GO:0004861 8.62 CDKN2B CDKN1A

Sources for Childhood T-Cell Acute Lymphoblastic Leukemia

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....